Role of the Independent Evaluation Group (IEG) Under the 3MDG Programme
Outline

1. 3MDG overview
2. Role of the IEG
3. The IEG structure and team
1. 3MDG Overview

- **Overarching Goal:** contribute to national progress towards the health MDGs through a rights based approach
- **3MDG Goal:** improved MNCH and reduction in communicable diseases burden in areas supported by the 3MDG Fund
- **3MDG Purpose:** Increased access and availability of:
  - Essential MNCH services for poorest and most vulnerable
  - HIV, TB and malaria interventions for populations not covered by the Global Fund
3MDG Programme
Component 1

- Component 1: Increased availability and accessibility of essential MNCH services
- Component 2: Flexible & strategic support for HIV, TB and malaria interventions (not covered by the Global Fund)
- Component 3: Complementary Health Systems Strengthening (HSS) to support long-term sustainability
3MDG M&E Strategy

Core Structures

**Fund Board**
Donor representatives + 3 independent experts oversee Fund Manager

**Fund Manager**
Contracted by the Board to manage implementation of all components of the Fund in accordance with Fund policy

Supporting Structures

**Senior Consultation Group**
Elected representatives of Implementing Partners Forum + representative of the MOH provide advice to the Fund Board

**Evaluation Group**
Contracted to provide independent evaluation services

ITAD, Ltd. & DMR-LM
2. Role of the IEG

• Our role is to provide oversight and ensure credible and useful data to inform management decisions, and effectiveness, efficiency, equity and sustainability of the 3MDG programme

• Therefore we will:
  – Build M&E capacity of the 3MDG team
  – Review proposed programme evaluations and data collection tools and methods (particularly surveys)
  – Conduct a midterm and final evaluation
  – Evaluate the impact of Component 1
Deliverable 1
Evaluation Framework (within 6 months)

• Articulates the 3MDG Fund Theory of Change (ToC)—basis for the programme logframe and all evaluation
• Identifies key questions for evaluation (impact, success, value for money)
• Considers various impact evaluation designs, and addresses how different methodologies address differential impacts
• Informs the baseline
Deliverable 2
Progress Reports

• Critical analysis of 3MDG annual progress reports
• Report against the workplan
• Financial updates
• Annual RDQA of the FMO
• Terms of Reference/research protocols for special evaluations/studies/reviews in line with the government research agenda and the newly formed TSG for M&E
Deliverable 3
Mid-Term Evaluation

• Tracks progress and recommends changes by 30 months after Fund inception
• Before end of 2nd Quarter 2015
Deliverable 4
Final Evaluation

- Includes lessons learned within 5 years after Fund inception
- Before 2\textsuperscript{nd} Quarter 2017
Deliverable 5
Impact Evaluation

• To be contracted after inception phase
Guiding Approach of the IEG

- Utilization Focused Evaluation Model
  - Engage key stakeholders in process to ensure credibility and use of findings
  - Can include any type of approach or methodology
  - Key stakeholders inform decisions in the evaluation process, and guide evaluators to ensure use of findings
    - Identify evaluation questions and clarify how their data will be used to inform decision making
    - Inform data collection and analysis
    - Guide appropriate communication of findings
Methods Overview

1. Kick-off Meeting with Fund Manager
2. Initial Stakeholder Consultations
3. Theory of Change Workshops
4. Establishing the Evaluation Framework (Baseline Studies)
5. Mixed Methods (quantitative and qualitative)
6. Initial Design Document
7. Semi-Annual Progress Reports
8. Mid-Term Evaluation
9. Final Evaluation
10. Impact Evaluation - Special Evaluations, Studies,
3. The IEG Structure & Team

Support Team
- Michele Gross (EHG)
- Sam McPherson (ITAD)
- Anette Cramer (EHG)

Core Team
- Team Leader: Donna Podems
- Deputy Team Leader: Michael Miner
- Epidemiologist: Khynn Than Win
- Operations Manager: Choo Phuah
- MNCH Expert: Katherine Ba-Thike

ITAD, Ltd. & DMR-LM
Dr. Donna Podems – TL
(PhD Evaluation & Org Development)

- Lecturer and Research Fellow at Stellenbosch University, Stellenbosch, South Africa
- 20 years evaluation experience
- Leads teams on implementation, outcome and impact evaluations in Africa and Asia for donors (e.g. DFID, AusAID, USAID) nonprofits and governments
- Serves as a Board Member of the American Evaluation Association, past board member of South African M&E Association, member of the European Evaluation Association and International Development Evaluator's Association
Michael Miner – DTL
(AM International Develop & Evaluation)

- Led/Co-Led over 70 evaluations for bilateral donors (AusAID, CIDA, DFID, Sida, USAID); multilateral donors (WB, UN); & INGOs (SCF, Plan, World Vision)
- Carried out monitoring of bi/multilateral programmes in governance & health for ≥20 years in 9 regional countries
- Served on UNIAP (Human Trafficking) Management Board for COMMIT (6 country Mekong program); represented Canada on Board working with: UNDP, UNFPA, UNICEF, UNODC, UNESCO, IOM, SAVE, USAID, AusAID, NORAD
- Served as Regional Director (2004-10) for Canada’s flagship ASEAN regional ‘rights based ‘ program focused on women and children, migrant workers and ethnic minorities.
- Conducted relevant evaluations: TL -UNICEF Maternal and Child Health program (AusAID funded), PNG; Basics–MCH, Timor Leste; Health Sector Evaluator for $500mill Canada Fund for Africa -HIV/AIDS - IAVI, polio and MDGs
Choo Phuah – Ops Manager  
(MA Public Administration)

• Strong understanding of overall context and working environment in Myanmar
• Worked in Myanmar since 1990 for UN, international and local NGOs -- Country Director for International HIV/AIDS Alliance in Myanmar from 2004-2009 and currently working as consultant based in-country
• Expertise in sexual and reproductive health including HIV and AIDS
• Experienced in participatory methodologies and civil society development
• Good working knowledge of Myanmar language
Dr. Katherine Ba-Thike - MNCH Expert (Ob/Gyn, MSc Health Systems Management)

- Seasoned ObGyn (20 yrs. in Myanmar) and Fellow of the Royal College of Obstetricians and Gynecologists, UK
- Served as faculty - University of Medicine 1,2 & Mandalay
- Acted as Adviser to RH Programmes (UNFPA Regional Technical Services Team for East and South-east Asia) - developing, assisting in implementation and evaluating country programmes
- Served (8 yrs.) as Area Manager for Asia and Pacific with the Department of RH and Research (WHO, Geneva) – strengthening research capacity for institutions in low-income countries and TA to RH Programmes
- Consulting for WHO and UNFPA – TL (national team) ICPD Beyond 2014 Review for Myanmar; TL (national team) for MDG Review for Myanmar; RH Expert for the UNFPA Asia and Pacific Regional Office.
Dr. Khynn Than Win  
(MD, MPH (Epidemiology)

- Implemented community programs for disease control and intervention >10 yrs.
- Served as a team member on the 3DF Final Evaluation Team.
- Developed, as part of a team, M&E systems as part of the overall HMIS in Myanmar
- Undertaken (more than 13 yrs.) design of evaluation frameworks
- Conducted and published both qualitative and quantitative research as a Research Officer.
- Acted as a Scientist in the disease control programs (WHO- Nepal)
- Developed capacity building of General Practitioners and AMWs with MMA-RH project
Pool of Experts
Anita Alban – Health Economist (BSc Economics)

- Served as Health Economist on 3DF Final Evaluation
- Seasoned Evaluation TL and Health Economics Expert
- Works widely in Asia including: Myanmar; Bangladesh; Bhutan; Cambodia; India; Indonesia; Malaysia; Maldives; Mongolia; Nepal; Pakistan; Sri Lanka; Thailand; & Vietnam
- Serves as an external Associate Professor at the University of Copenhagen/Master of International Health Programme
- Led numerous economic evaluations and VfM studies
- Worked as director of research in Danish Institute of Health Services Research, in UNAIDS as the lead economist, and has for the past 12 years worked a consultant in developing countries.